Eris Lifesciences Limited
3,621words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
28%
FINANCIAL HIGHLIGHTS (Rs. Crore) Operating Revenue Ebitda PAT Q4 FY25 705 252 102 Growth YoY 28% 70% 28% • Q4 consolidated operating revenue up by 28% to Rs. 705 cr. • Q4 - Margin and Fixed C
70%
NCIAL HIGHLIGHTS (Rs. Crore) Operating Revenue Ebitda PAT Q4 FY25 705 252 102 Growth YoY 28% 70% 28% • Q4 consolidated operating revenue up by 28% to Rs. 705 cr. • Q4 - Margin and Fixed Cost S
Rs. 705
Q4 FY25 705 252 102 Growth YoY 28% 70% 28% • Q4 consolidated operating revenue up by 28% to Rs. 705 cr. • Q4 - Margin and Fixed Cost Synergies continue to accrue • Gross Margin down by 269 bps •
269 bps
to Rs. 705 cr. • Q4 - Margin and Fixed Cost Synergies continue to accrue • Gross Margin down by 269 bps • Fixed Expenses (% of Revenue) down 1,153 bps yoy • Q4 EBIDTA Rs. 252 cr. - yoy growth of 70%
1,153 bps
ynergies continue to accrue • Gross Margin down by 269 bps • Fixed Expenses (% of Revenue) down 1,153 bps yoy • Q4 EBIDTA Rs. 252 cr. - yoy growth of 70%*, Q4 EBIDTA Margin of 36% • Q4 PAT of Rs. 102 c
Rs. 252
• Gross Margin down by 269 bps • Fixed Expenses (% of Revenue) down 1,153 bps yoy • Q4 EBIDTA Rs. 252 cr. - yoy growth of 70%*, Q4 EBIDTA Margin of 36% • Q4 PAT of Rs. 102 cr. – yoy EPS growth 28% •
36%
of Revenue) down 1,153 bps yoy • Q4 EBIDTA Rs. 252 cr. - yoy growth of 70%*, Q4 EBIDTA Margin of 36% • Q4 PAT of Rs. 102 cr. – yoy EPS growth 28% • OCF-to-EBIDTA ratio - 111% in Q4 • • FY25 ROCE
Rs. 102
1,153 bps yoy • Q4 EBIDTA Rs. 252 cr. - yoy growth of 70%*, Q4 EBIDTA Margin of 36% • Q4 PAT of Rs. 102 cr. – yoy EPS growth 28% • OCF-to-EBIDTA ratio - 111% in Q4 • • FY25 ROCE 15% (up from 11% in FY
111%
%*, Q4 EBIDTA Margin of 36% • Q4 PAT of Rs. 102 cr. – yoy EPS growth 28% • OCF-to-EBIDTA ratio - 111% in Q4 • • FY25 ROCE 15% (up from 11% in FY24) Adjusted ROCE ** 20% (up from 19% in FY24) Sourc
15%
• Q4 PAT of Rs. 102 cr. – yoy EPS growth 28% • OCF-to-EBIDTA ratio - 111% in Q4 • • FY25 ROCE 15% (up from 11% in FY24) Adjusted ROCE ** 20% (up from 19% in FY24) Source – Audited Financial State
11%
Rs. 102 cr. – yoy EPS growth 28% • OCF-to-EBIDTA ratio - 111% in Q4 • • FY25 ROCE 15% (up from 11% in FY24) Adjusted ROCE ** 20% (up from 19% in FY24) Source – Audited Financial Statements * Incl
20%
8% • OCF-to-EBIDTA ratio - 111% in Q4 • • FY25 ROCE 15% (up from 11% in FY24) Adjusted ROCE ** 20% (up from 19% in FY24) Source – Audited Financial Statements * Includes the effect of one-time ite